Mena Esther, Sanli Yasemin, Marcus Charles, Subramaniam Rathan M
Molecular Imaging Program, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Building 10, Room B3B402, Bethesda, MD 20892-1763, USA.
Department of Radiology, The University of Texas Southwestern Medical Center, Dallas, TX, USA.
PET Clin. 2017 Oct;12(4):449-458. doi: 10.1016/j.cpet.2017.05.002. Epub 2017 Jul 14.
Recent advances in genomic profiling and sequencing of melanoma have provided new insights into the development of the basis for molecular biology to more accurately subgroup patients with melanoma. The development of novel mutation-targeted and immunomodulation therapy as a major component of precision oncology has revolutionized the management and outcome of patients with metastatic melanoma. PET imaging plays an important role in noninvasively assessing the tumor biological behavior, to guide individualized treatment and assess response to therapy. This review summarizes the recent genomic discoveries in melanoma in the era of targeted therapy and their implications for functional PET imaging.
黑色素瘤基因组分析和测序的最新进展为分子生物学基础的发展提供了新的见解,以便更准确地对黑色素瘤患者进行亚组分类。新型突变靶向和免疫调节疗法作为精准肿瘤学的主要组成部分,彻底改变了转移性黑色素瘤患者的管理和治疗结果。PET成像在无创评估肿瘤生物学行为、指导个体化治疗和评估治疗反应方面发挥着重要作用。本综述总结了靶向治疗时代黑色素瘤的最新基因组发现及其对功能性PET成像的意义。